Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in the context of hyperparathyroidism in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, women only.

One hundred consecutive ambulatory postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL were included in a randomized, prospective, open label study.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

Changes observed during the 90 days of the study in circulating PTH levels were the primary endpoint, while changes in serum 25(OH)D levels were assessed as secondary endpoint.

What Was Measured

PubMed files the paper under topics including Calcium Carbonate, Calcium Compounds, Carbonates, Drug Combinations, Hyperparathyroidism, Secondary, Lactates and Postmenopause.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in people with hyperparathyroidism.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2002 (Aging clinical and experimental research), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, Hyperparathyroidism research.